[Computerized tomography with lipiodol in the assessment of hepatocellular carcinoma].
F Gattoni, Stamatia Dova, F Volterrani, M Le Blanc, C Uslenghi
Abstract
F Gattoni, Stamatia Dova, F Volterrani, M Le Blanc, C Uslenghi
Abstract
In this paper we report the results obtained with Lipiodol CT in 39 patients with hepatocellular carcinoma (HCC). All patients had focal or multifocal nodular HCC with FNB confirmation and were all submitted to CT 15-20 days after the injection of Lipiodol in common or proper hepatic arteries during an angiographic maneuver. Lipiodol CT showed all the lesions US had demonstrated and depicted more lesions in 12 patients (30.7%)--67 lesions in all. The lesions demonstrated by Lipiodol CT were always smaller than 2 cm: 9/12 had been missed by US, 6/12 by CT and 7/12 by arteriography. In 34/67 lesions (50.7%) enhancement was homogeneous, in 29/67 (43.2%) inhomogeneous and in 4/67 cases (5.9%) Lipiodol was not retained. Lipiodol uptake depended on lesion size: if the lesion was 1-2 cm, uptake was homogeneous, while bigger lesions exhibited inhomogeneous uptake. Lesions bigger than 4 cm exhibited no Lipiodol uptake and were necrotic. A surgical resection was performed in 21/39 patients (53.8%). To conclude, Lipiodol CT is a valuable technique in the preoperative screening of HCC, particularly in the detection of additional lesions: in our series they were demonstrated in 30.7% of patients.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
In this paper we report the results obtained with Lipiodol CT in 39 patients with hepatocellular carcinoma (HCC). All patients had focal or multifocal nodular HCC with FNB confirmation and were all submitted to CT 15-20 days after the injection of Lipiodol in common or proper hepatic arteries during an angiographic maneuver. Lipiodol CT showed all the lesions US had demonstrated and depicted more lesions in 12 patients (30.7%)--67 lesions in all. The lesions demonstrated by Lipiodol CT were always smaller than 2 cm: 9/12 had been missed by US, 6/12 by CT and 7/12 by arteriography. In 34/67 lesions (50.7%) enhancement was homogeneous, in 29/67 (43.2%) inhomogeneous and in 4/67 cases (5.9%) Lipiodol was not retained. Lipiodol uptake depended on lesion size: if the lesion was 1-2 cm, uptake was homogeneous, while bigger lesions exhibited inhomogeneous uptake. Lesions bigger than 4 cm exhibited no Lipiodol uptake and were necrotic. A surgical resection was performed in 21/39 patients (53.8%). To conclude, Lipiodol CT is a valuable technique in the preoperative screening of HCC, particularly in the detection of additional lesions: in our series they were demonstrated in 30.7% of patients.
Key concepts: Lipiodol, Medicine, Hepatocellular carcinoma, Lesion, Radiology, Homogeneous, Interventional radiology, Neuroradiology